Skip to content

Startup & venture capital news

Oyster Therapeutics raises USD 60m for neuroscience drug development

4BIO Capital leads the Series A-2 financing.

By /

LinkedInX
Oyster Therapeutics: Oyster Therapeutics raises USD 60m for neuroscience drug development

Oyster Therapeutics raised USD 60 million in Series A-2 financing led by 4BIO Capital. Eli Lilly, Actium Group, CE Ventures and TOHO Ventures joined existing investors including Syncona, Oxford Science Enterprises, Mission BioCapital and MGB Ventures. The London company, previously known as Kesmalea Therapeutics, develops targeted protein degraders for neurological diseases. The capital will advance an oral tau degrader toward clinical development and support its SELFTAC platform. Oyster’s programmes remain preclinical, and the announcement does not report completed human efficacy. The company also adopted the Oyster name alongside the financing.

Keep reading

More Funding

All stories